Ceftazidime

Ceftazidime is a third-generation parenteral cephalosporin bactericidal antibiotic recognized for its high intrinsic activity against Pseudomonas aeruginosa. It acts by inhibiting bacterial cell wall synthesis. Indicated for severe hospital-acquired pneumonia, pseudomonal bacteremia, empirical therapy for febrile neutropenia, complicated urinary tract infections, cystic fibrosis pulmonary exacerbations, and intra-abdominal infections.

Ceftazidime is a third-generation parenteral cephalosporin bactericidal antibiotic recognized for its high intrinsic activity against Pseudomonas aeruginosa. It acts by inhibiting bacterial cell wall synthesis. Indicated for severe hospital-acquired pneumonia, pseudomonal bacteremia, empirical therapy for febrile neutropenia, complicated urinary tract infections, cystic fibrosis pulmonary exacerbations, and intra-abdominal infections.

Ceftazidime is a third-generation parenteral cephalosporin bactericidal antibiotic recognized for its high intrinsic activity against Pseudomonas aeruginosa. It acts by inhibiting bacterial cell wall synthesis. Indicated for severe hospital-acquired pneumonia, pseudomonal bacteremia, empirical therapy for febrile neutropenia, complicated urinary tract infections, cystic fibrosis pulmonary exacerbations, and intra-abdominal infections.

Ceftazidime and Tazobactam is a parenteral combination designed to combat resistant Pseudomonas aeruginosa and beta-lactamase-producing Enterobacteriaceae. Ceftazidime provides high intrinsic anti-pseudomonal bactericidal activity, while tazobactam inhibits beta-lactamases that would otherwise hydrolyze the cephalosporin ring. Indicated for nosocomial pneumonia, febrile neutropenia, complicated intra-abdominal infections, and severe urinary tract infections.

Ceftazidime and Tazobactam is a parenteral combination designed to combat resistant Pseudomonas aeruginosa and beta-lactamase-producing Enterobacteriaceae. Ceftazidime provides high intrinsic anti-pseudomonal bactericidal activity, while tazobactam inhibits beta-lactamases that would otherwise hydrolyze the cephalosporin ring. Indicated for nosocomial pneumonia, febrile neutropenia, complicated intra-abdominal infections, and severe urinary tract infections.

Ceftazidime and Avibactam is an advanced carbapenem-sparing antimicrobial agent. Ceftazidime is an anti-pseudomonal third-generation cephalosporin, and avibactam is a novel non-beta-lactam beta-lactamase inhibitor that inhibits class A (including KPC carbapenemases), class C (AmpC), and certain class D (OXA-48) beta-lactamases. Indicated for complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria.